Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 8051 to 8100 of 8150 results

  1. MT547 QuickChange Incontinence Wrap for urinary incontinence in men (MIB237)

      Status ...

    Medical technologies guidance
    Topic selection

  2. Suspected cancer update

    In development [GID-QS10176] Expected publication date: TBC

    Quality standard
    In development

  3. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued

  4. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  5. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  6. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  7. Pembrolizumab with platinum-based chemotherapy then pembrolizumab maintenance for treating advanced or recurrent endometrial cancer ID6381

    In development [GID-TA11461] Expected publication date: TBC

    Technology appraisal guidance
    In development

  8. Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]

    Awaiting development [GID-TA11008] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Asthma: diagnosis, monitoring and chronic asthma management

    In development [GID-NG10186] Expected publication date: TBC

    NICE guideline
    In development

  10. NVK-002 for treating myopia in people 3 to 17 years TSID 11961

      Status ...

    Technology appraisal guidance
    Topic selection

  11. Dapagliflozin for treating chronic kidney disease [ID6411]

    In development [GID-TA11547] Expected publication date: 12 February 2025

    Technology appraisal guidance
    In development

  12. Durvalumab with or without bevacizumab for adjuvant treatment of resected or ablated hepatocellular carcinoma at high risk of recurrence [ID6428]

    Awaiting development [GID-TA11538] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued [GID-MT557]

    Medical technologies guidance
    Discontinued

  14. GID-MT563 NPi-200 for pupillary light reflex in critical care patients

    Discontinued [GID-MT563]

    Medical technologies guidance
    Discontinued

  15. Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]

    In development [GID-TA11062] Expected publication date: 30 October 2024

    Technology appraisal guidance
    In development

  16. Acoramidis for treating transthyretin-mediated amyloidosis cardiomyopathy [ID6354]

    Awaiting development [GID-TA11415] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  17. Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]

    In development [GID-TA11369] Expected publication date: 14 August 2024

    Technology appraisal guidance
    In development

  18. Single-step scaffold insertion for repairing symptomatic chondral knee defects

    Awaiting development [GID-IPG10364] Expected publication date: 17 September 2024

    Interventional procedures guidance
    Awaiting development

  19. Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer ID6256

    In development [GID-TA11279] Expected publication date: TBC

    Technology appraisal guidance
    In development

  20. Sparsentan for treating primary IgA nephropathy [ID6308]

    In development [GID-TA11359] Expected publication date: 30 April 2025

    Technology appraisal guidance
    In development

  21. Nivolumab for adjuvant treatment of completely resected melanoma at high risk of recurrence in people aged 12 and over [ID6189]

    In development [GID-TA11138] Expected publication date: TBC

    Technology appraisal guidance
    In development

  22. Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]

    In development [GID-TA11033] Expected publication date: TBC

    Technology appraisal guidance
    In development

  23. Troriluzole for spinocerebellar ataxia TS ID 12013

    Awaiting development [GID-TA11549] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  24. Pembrolizumab with chemotherapy for neoadjuvant and adjuvant treatment of cisplatin-eligible muscle-invasive bladder cancer [ID6219]

    Awaiting development [GID-TA11137] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  25. Amivantamab with carboplatin and pemetrexed for untreated EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer ID5110

    In development [GID-TA11023] Expected publication date: TBC

    Technology appraisal guidance
    In development

  26. IgPro20 for treating dermatomyositis TS ID 12014

    Awaiting development [GID-TA11550] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  27. The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)

    Discontinued [GID-MT517]

    Medical technologies guidance
    Discontinued

  28. Tideglusib for treating congenital or childhood onset myotonic dystrophy [ID3915 ]

    Awaiting development [GID-TA10791] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  29. Robot-assisted surgery for soft-tissue procedures: early value assessment

    In development [GID-HTE10040] Expected publication date: 21 January 2025

    Health technology evaluations
    In development

  30. Eplontersen for treating transthyretin-related amyloidosis cardiomyopathy TSID 12015

    Awaiting development [GID-TA11551] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  31. BI 1015550 for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis TS ID 12016

    Awaiting development [GID-TA11552] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  32. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development [GID-NG10216] Expected publication date: TBC

    NICE guideline
    In development

  33. Menopause: diagnosis and management

    In development [GID-NG10241] Expected publication date: TBC

    NICE guideline
    In development

  34. Pneumonia: diagnosis and management (update)

    In development [GID-NG10357] Expected publication date: TBC

    NICE guideline
    In development

  35. Women's and reproductive health guidelines

    This webpage covers all NICE's guidelines on women's and reproductive health. The table presents the guidelines alphabetically. Updates planned or in...

    NICE guideline
    In development

  36. News

    NICE and NHS England announce plan to enable innovative tech to be adopted quicker NHS patients in England will benefit from faster

  37. Depemokimab for treating severe eosinophilic asthma in people 12 years and over TSID 12017

    Awaiting development [GID-TA11553] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  38. Cardiovascular risk assessment and lipid modification

    Awaiting development [GID-QS10187] Expected publication date: TBC

    Quality standard
    Awaiting development

  39. NICE

    NICE helps practitioners and commissioners get the best care to patients, fast, while ensuring value for the taxpayer.

  40. Selpercatinib for advanced thyroid cancer with RET alterations that has not been treated with systemic therapy [ID6132]

    In development [GID-TA11047] Expected publication date: 21 August 2024

    Technology appraisal guidance
    In development

  41. Blinatumomab with chemotherapy for consolidation treatment of Philadelphia-chromosome-negative CD19-positive B-precursor acute lymphoblastic leukaemia with no measurable residual disease ID6405

    In development [GID-HTE10035] Expected publication date: TBC

    Health technology evaluations
    In development

  42. Sirolimus for treating facial angiofibroma from tuberous sclerosis complex in people 6 years and older [ID6440]

    In development [GID-TA11554] Expected publication date: TBC

    Technology appraisal guidance
    In development

  43. Zanubrutinib with obinutuzumab for treating relapsed or refractory B-cell follicular lymphoma after 2 or more treatments [ID6416]

    Awaiting development [GID-TA11520] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  44. Artificial intelligence (AI) technologies for assessing skin lesions referred on the urgent suspected cancer pathway

    In development [GID-HTE10047] Expected publication date: TBC

    Health technology evaluations
    In development

  45. Empagliflozin for preventing cardiovascular events after acute myocardial infarction [ID6240]

    In development [GID-TA11265] Expected publication date: TBC

    Technology appraisal guidance
    In development

  46. Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 4 or more therapies [ID2701]

    In development [GID-TA10568] Expected publication date: TBC

    Technology appraisal guidance
    In development

  47. Zoll ThermoGuard XP for Intravascular Temperature Management

      Status ...

    Medical technologies guidance
    Topic selection

  48. Natural Cycles for monitoring fertility

      Status ...

    Medical technologies guidance
    Topic selection

  49. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B [ID3812]

    In development [GID-TA10699] Expected publication date: TBC

    Technology appraisal guidance
    In development

  50. Ivacaftor–tezacaftor–elexacaftor, tezacaftor–ivacaftor and lumacaftor–ivacaftor for treating cystic fibrosis [ID3834]

    In development [GID-TA11187] Expected publication date: TBC

    Technology appraisal guidance
    In development